Fresenius Medical Care Showcases Innovations at ASN Kidney Week 2025

Fresenius Medical Care will present ASN Kidney Week 2025 data showing high-volume hemodiafiltration (HDF) is associated with fewer cardiovascular- and fluid-related hospitalizations and will unveil AI tools to support safe implementation, according to the Fresenius Medical Care press release.

Company-reported real-world evidence across multiple abstracts—including an oral presentation—frames endpoints specifically as cardiovascular- and fluid-related hospitalizations in routine dialysis settings. These data suggest that high-volume HDF may reduce hospitalizations for patients at elevated fluid or cardiac risk.

Fresenius will also introduce clinician-facing AI tools to support implementation and safety. One model predicts 31-day fall risk; a chatbot delivers verified clinical sources and real-time guidance for HDF setup and workflows, per the release. These capabilities are positioned to strengthen patient-safety monitoring, provide decision support, and streamline unit-level HDF integration.

Fresenius outlines a U.S. rollout strategy focused on staff training, phased clinic implementation, integrated AI support, and ongoing performance tracking. The company emphasizes stepwise scaling to preserve safety while enabling broader adoption in U.S. dialysis centers.